Condition: Advanced Solid Tumors · Relapsed/Refractory B-cell Lymphoma · Sponsor: InSilico Medicine Hong Kong Limited
The goal of this clinical trial is to study ISM8207 in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma. The primary objective is to evaluate the safety and tolerability of ISM8207 orally administered in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma
This description comes directly from the study's public registry record.
Yichen Liu · 021-50831718 · Insilico-Clinicaltrial@insilico.ai
Juan Xu · Insilico-Clinicaltrial@insilico.ai
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The First Affiliated Hospital of Nanchang University | Nanchang, Jiangxi, China | Recruiting |
| Shanghai Jiao Tong University School of Medicine-Ruijin Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Tianjin Medical University Cancer Institute&Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06445517